Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot PharmaphorumA unanimous endorsement from FDA advisors brings Moderna's RNA-based seasonal influenza vaccine a step closer to US approval.Infectious DiseaseRead full story pharminent June 19, 2026 (Last updated: June 22, 2026) Pharmaphorum A unanimous endorsement from FDA advisors brings Moderna’s RNA-based seasonal influenza vaccine a step closer to US approval. Infectious Disease Read full story Post navigation Previous: FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’Next: Biogen to acquire RayThera for up to $1bn Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026